منابع مشابه
Advanced Practitioners Are Not Mid-Level Providers
W hile I was completing my nurse practitioner program, I interviewed for a PRN position at a large private oncology practice. The oncolo-gist with whom I spoke was aware that I was continuing my graduate nursing education; she spoke of how they might consider me for employment as an oncology nurse practitioner upon my graduation. As she talked about her current staff, she used a descriptor I ha...
متن کاملExpanding the role of advanced nurse practitioners--risks and rewards.
As the 2014 expansion of coverage mandated by the Affordable Care Act (ACA) looms larger, one question with no ready answer is how health care providers, policymakers, and payers will cope with an expected surge in patient demand for services. A shortage of primary care physicians to treat newly insured persons is the most immediate health workforce issue, but when added to the nation’s populat...
متن کاملBiosimilars in the United States: Considerations for Oncology Advanced Practitioners
Biosimilars will enter the US market soon, potentially lowering costs and increasing patient access to important oncology biologics. Biosimilars are highly similar, but not identical, to their reference product. Subtle variations arise due to their inherent complexity and differences in manufacturing. Biosimilars are not generic drugs. They will be approved through a separate US regulatory path...
متن کاملDeveloping the role of advanced nurse practitioners in mental health.
This article describes the development of an advanced nurse practitioner (ANP) service in mental health. The ANPs worked within an existing hospital at night team based at Crosshouse Hospital, a district general hospital in Kilmarnock. Set against the agenda of Modernising Nursing Careers and Modernising Medical Careers, the article describes the professional and organisational background to th...
متن کاملOverview of the CLEOPATRA Trial: Implications for Advanced Practitioners
G enomic biomarkers have long been known as predictors of pharmacokinetic differences among individuals that lead to differences in plasma drug exposure. Overexpression of the human epithelial growth factor receptor (HER2) proto-oncogene is seen in about 25% of human breast cancer and leads to a more aggressive tumor phenotype with a poor prognosis (Rexer & Arteaga, 2012). In recent years, this...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Dialysis & Transplantation
سال: 2010
ISSN: 0090-2934,1932-6920
DOI: 10.1002/dat.20424